Variable economic injury for the apple leafcurling midge and modelling of population abundance of this emerging pest
Daniel Cormier
Researcher, Ph.D.
450 653-7368
ext 360
Description
The apple leafcurling midge (ALM), Dasineura mali (Kieffer), is a new apple pest in Québec. Its impact on the growth and future yields of young apple trees is still little known. The aim of the project is to explore the pest’s phenology, establish variable economic injury thresholds, and incorporate the results into a phenology model in CIPRA.
Objective(s)
- Assess the annual and cumulative impact of ALM infestations on the growth and yield of young apple trees in the establishment phase
- Monitor the abundance of ALM adults in relation to infestation levels in commercial orchards in three apple growing regions
- Model adult populations and develop a variable economic injury threshold
From 2014 to 2017
Project duration
Fruit production
Activity areas
Pest, weed, and disease control
Service
This work will help apple growers control new pests more effectively.
Partners
Ministère de l'Agriculture, des Pêcheries et de l'Alimentation du Québec, Agriculture et Agroalimentaire Canada, Centre de recherche agroalimentaire de Mirabel
Publications
Summary sheet • Franz Vanoosthuyse
Vanoosthuyse, F. 2016. La cécidomyie du pommier, Dasineura mal (Keif.) : un nouveau ravageur des pommiers au Québec. IRDA. 3 p. DownloadThis may interest you
Using apple maggot mass trapping with attracticidal spheres to cut back on insecticide applications in orchards
This project seeks to reduce the use of chemical insecticides in orchards by controlling apple maggot populations using mass trapping.
Researcher: Daniel Cormier
Selecting low-risk insecticides to control cranberry weevil on cranberry farms
The aim of this two-year project was to determine the efficacy of various pesticides in the field.
Researcher: Annabelle Firlej
Tailoring apple scab control strategies to the properties of the fungicides utilized
Developing a new scab control strategy based on selecting the lowest-risk products that best fit the circumstances at hand, and tailoring the doses accordingly.
Researcher: Vincent Philion
